ArticleNPJ precision oncology2026
Supervoxel-based multimodal MRI biomarkers reveal tumor heterogeneity in high-grade glioma for prognostic stratification and therapy response prediction.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
High-grade glioma (HGG) exhibits substantial biological heterogeneity, which complicates prognosis and treatment, and clarifying the interplay between proliferating tumor cells and tumor-associated microvasculature may improve patient outcomes. We prospectively enrolled 221 patients with HGG from four institutions and integrated diffusion-weighted and dynamic contrast-enhanced MRI within a supervoxel-based framework to delineate tumor subregions termed density-enhancement compounded voxels (DECV). Four DECV subregions (DECV1-4) with distinct imaging characteristics were identified. DECV4, characterized by low apparent diffusion coefficient and gradual enhancement, was strongly associated with tumor aggressiveness and treatment resistance. Clustering analysis further revealed two DECV phenotypes that differed significantly in progression-free and overall survival; phenotype II showed a higher DECV4 proportion and a poorer prognosis. DECV phenotypes outperformed conventional imaging markers as independent predictors of survival and were validated in an independent cohort. These DECV-based imaging phenotypes provide a robust, non-invasive biomarker for characterizing HGG heterogeneity and show potential to enhance prognostic stratification and guide personalized therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.